UBS: Maintaining Cinda Biotech's (01801) “Buy” Rating Target Price of HK$137.4

The Zhitong Finance App learned that UBS released a research report stating that six new products under Cinda Biotech (01801) and new indications of cindilizumab have been included in the latest edition of the “National Basic Medical Insurance, Maternity Insurance and Work Injury Insurance Drug Catalogue (2025)”. Furthermore, Cinda Biotech has officially been included in the Hang Seng Index starting today (8th). UBS maintains its “buy” rating with a target price of HK$137.4.

According to UBS, the positive impact of the above news mainly includes: sales of new products (targets such as IGF-1R, EGFR, BTK, ROS1, KRAS G12C, RET, etc.) are expected to grow rapidly in 2026; at the same time, tiverpotide diabetes indications are included in the medical insurance catalogue, which has a positive impact on the Mast peptide expected to be marketed in 2026, but it is necessary to pay attention to its price reduction. Furthermore, the inclusion of the company's shares in the Hang Seng Index is expected to further enhance liquidity.